AZN-OLD
AstraZeneca PLC
AstraZeneca PLC historical holders
total: 6
Parnassus Endeavor Fund AstraZeneca PLC transactions over time
- Total transactions:
- 6
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 1
- Held since:
- 2024 Q4
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q1
Parnassus Endeavor Fund has been an institutional investor in AstraZeneca PLC (AZN-OLD) since 2024 Q4. According to 2026 Q2 report, Parnassus Endeavor Fund doesn't hold any shares. The fund/company first acquired AZN-OLD in 2024 Q4, initially purchasing about 1.18M shares. Since the initial investment, Parnassus Endeavor Fund has made 5 more transactions in this position.
When did Parnassus Endeavor Fund exit their AZN-OLD position?
Parnassus Endeavor Fund no longer holds AstraZeneca PLC (AZN-OLD). They sold off their entire position in 2026 Q1, closing out an investment that began in 2024 Q4.
When did Parnassus Endeavor Fund first invest in AZN-OLD?
Parnassus Endeavor Fund first invested in AstraZeneca PLC (AZN-OLD) in 2024 Q4 at the reported quarter-end price of $65.52 per share, acquiring 1,178,323 shares in their initial purchase.
What is Parnassus Endeavor Fund's average cost basis for AZN-OLD?
Based on historical transaction data, Parnassus Endeavor Fund's estimated cost basis for AstraZeneca PLC (AZN-OLD) is approximately $66.03 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $66.03
- Weighted AVG sell price:
- $91.93
AZN-OLD transactions history by Parnassus Endeavor Fund
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$91.93
|
|
-100% (-1,227,628)
|
-2.37%
|
|
2025 Q4
|
2.37%
|
1,227,628
|
$91.93
|
$112,855,842
|
-4.43% (-56,963)
|
-0.11%
|
|
2025 Q3
|
2.09%
|
1,284,591
|
$76.72
|
$98,553,822
|
+0.39% (+5,030)
|
+0.01%
|
|
2025 Q2
|
1.97%
|
1,279,561
|
$69.88
|
$89,415,723
|
+4.77% (+58,277)
|
+0.09%
|
|
2025 Q1
|
2.00%
|
1,221,284
|
$73.50
|
$89,764,374
|
+3.65% (+42,961)
|
+0.07%
|
|
2024 Q4
|
1.60%
|
1,178,323
|
$65.52
|
$77,203,723
|
new
|
+1.6%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.